#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Acute myeloid leukaemia Neoplasm malignant Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Ovarian cancer Colorectal cancer Hepatocellular carcinoma Asthma Dermatitis atopic Dementia Alzheimer's type Type 2 diabetes mellitus Breast cancer metastatic Non-small cell lung cancer metastatic More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Netherton's syndrome Albright's disease Metastatic gastric cancer Cerebral haemorrhage Thrombotic thrombocytopenic purpura Atopic keratoconjunctivitis Mitochondrial encephalomyopathy Colorectal cancer metastatic Myxoid liposarcoma Anti-glomerular basement membrane disease Small intestine leiomyosarcoma Clear cell papillary renal cell carcinoma Non-Hodgkin's lymphoma Solitary fibrous tumour Cognitive disorder More trials…

    Learn about Rare Diseases

    Mantle cell lymphoma stage II – Treatment Hereditary ataxia Arterial tortuosity syndrome – Trials in Disease Pleomorphic leiomyosarcoma – Life with Disease Kearns-Sayre syndrome Chondrosarcoma – Diagnostics Fabry’s disease Cholangitis sclerosing Antithrombin III deficiency – Diagnostics Optic glioma – Trials in Disease More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Canagliflozin GT-002 Trastuzumab Deruxtecan Pelacarsen Lacosamide Deferiprone Gozetotide Alf-18 Leucine Atazanavir Remibrutinib Folic Acid Fluoroestradiol F-18 Vo659 Adrc Gen1046 Osilodrostat Tolebrutinib Tadekinig Alfa Delandistrogene Moxeparvovec Diclofenac More therapies…

    Learn about Your Condition

    Encephalitis Japanese B Psychological trauma Congenital aplastic anaemia Nephroblastoma Post procedural hypotension Embolism venous Acute coronary syndrome Adrenal insufficiency Pyrexia Inborn error of metabolism Vomiting Synovial sarcoma Lichen planopilaris Sickle cell anaemia Diabetic retinopathy More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden
  1. Clinicaltrials.eu/
  2. Kliiniliste Uuringute Keskus OÜ

Kliiniliste Uuringute Keskus OÜ

Sobra Tn 54/1, Tartu, 50106, Estonia

Want to learn more about this study or check if you can participate? Contact us.

  • Study on the Effectiveness and Safety of ESK-001 and Apremilast for Patients with Moderate to Severe Plaque Psoriasis

    Not recruiting

    3 1 1
    Investigated Diseases:
    • Psoriasis
    Investigated Drugs:
    • Envudeucitinib
    • Apremilast
    Austria Estonia France Germany Hungary Latvia +3

  • Study of mRNA-1010 Influenza Vaccine Compared to Standard Flu Vaccine in Adults 50 Years and Older

    Not recruiting

    3 1 1 1
    Investigated Drugs:
    • A/Victoria/4897/2022 (H1N1)Pdm09-Like Strain (A/Victoria/4897/2022, Ivr-238)
    • B/Phuket/3073/2013-Like Virus (B/Phuket/3073/2013, Wild Type)
    • Cx-037231
    Belgium Bulgaria Estonia Finland Germany

  • Study on the Effectiveness and Safety of Vibozilimod for Adults with Moderate to Severe Plaque Psoriasis

    Not recruiting

    2 1
    Investigated Diseases:
    • Psoriasis
    Investigated Drugs:
    • Vibozilimod
    Estonia Poland

  • Study on Rosnilimab for Patients with Moderate to Severe Rheumatoid Arthritis

    Not recruiting

    2 1
    Investigated Diseases:
    • Rheumatoid arthritis
    Investigated Drugs:
    • Rosnilimab
    Belgium Estonia France Germany Hungary Italy +3

  • Study on the Effectiveness and Safety of Abatacept Biosimilar (DRL_AB) and Methotrexate for Patients with Moderate to Severe Rheumatoid Arthritis

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    • Rheumatoid arthritis
    Investigated Drugs:
    • Abatacept
    • Methotrexate
    Bulgaria Czechia Estonia Hungary Latvia Lithuania +2

  • Study on Tildrakizumab for Patients with Active Psoriatic Arthritis Who Have Previously Used Anti-TNF Therapy

    Not recruiting

    3 1 1
    Investigated Diseases:
    • Psoriatic arthropathy
    Investigated Drugs:
    • Tildrakizumab
    Czechia Estonia Germany Italy Poland Slovakia +1

  • Study on Long-Term Safety and Efficacy of Tildrakizumab for Adults with Psoriatic Arthritis

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    • Psoriatic arthropathy
    Investigated Drugs:
    • Tildrakizumab
    Czechia Estonia Germany Italy Poland Slovakia +1

  • Study on the Effects of Filgotinib for Adults with Active Axial Spondyloarthritis

    Not recruiting

    3 1 1
    Investigated Diseases:
    • Axial spondyloarthritis
    Investigated Drugs:
    • Filgotinib
    Belgium Bulgaria Croatia Czechia Estonia France +9

  • Study on the Effects of Vibozilimod for Adults with Moderate to Severe Atopic Dermatitis

    Not recruiting

    2 1 1
    Investigated Diseases:
    • Dermatitis atopic
    Investigated Drugs:
    • Vibozilimod
    Estonia Poland

  • Study on the Effects and Safety of Guselkumab for Patients with Active Psoriatic Arthritis

    Not recruiting

    3 1
    Investigated Diseases:
    • Psoriatic arthropathy
    Investigated Drugs:
    • Guselkumab
    Bulgaria Croatia Czechia Estonia Germany Greece +8
Previous Page
1 2 3

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!